BLA 761172 · Ridgeback Biotherapeutics
Ebanga
Ansuvimab-Zykl · Iv (Infusion) · Zaire Ebolavirus Glycoprotein-directed Antibody
NovelBreakthrough therapyPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Feb 18, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2020
Dec 21, 2020
Approved uses
1
Original approval plus efficacy supplements
Registered trials
3
1 Phase 3, 0 recruiting
FAERS reports
3
3 serious, 2 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Aug 13, 2026.
EBANGA is indicated for the treatment of infection caused by Orthoebolavirus zairense (formerly Zaire ebolavirus) in adult and pediatric patients, including neonates born to a mother who is RT-PCR positive for Orthoebolavirus zairense infection [see Dosage and Administration (2.2) and Clinical Studies (14) ]. EBANGA (ansuvimab-zykl) is an Orthoebolavirus zairense glycoprotein (EBOV GP)-directed human monoclonal antibody indicated for the treatment of infection caused by Orthoebolavirus zairense in adult and pediatric patients, including neonates born to a mother who is RT-PCR positive for Orthoebolavirus zairense infection. ( 1 ) Limitation of Use The efficacy of EBANGA has not been established for other species of the Orthoebolavirus and Orthomarburgvirus genera . Orthoebolavirus zairense can change over time, and factors such as emergence of resistance or changes in viral virulence could diminish the clinical benefit of antiviral drugs. Consider available information on drug susceptibility patterns for circulating Orthoebolavirus zairense strains when deciding whether to use EBANGA. Limitations of Use: The efficacy of EBANGA has not been established for other species of the Orthoebolavirus and Orthomarburgvirus genera. Orthoebolavirus zairense can change over time, and factors such as emergence of resistance, or changes in viral virulence could diminish the clinical benefit of antiviral drugs. Consider available information on drug susceptibility patterns for circulating Orthoebolavirus zairense strains when deciding whether to use EBANGA.
Mechanism: Ansuvimab-zykl is a recombinant human monoclonal antibody with antiviral activity against Orthoebolavirus zairense [see Microbiology (12.4) ] .
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 21, 2020 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyOrphanLabelLetterReview
1 products under this application
- EBANGA · ANSUVIMAB-ZYKL 400MG/VIAL · POWDER, IV (INFUSION) · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Ansuvimab" as an intervention, any sponsor and status, largest first.
- Investigational Therapeutics for the Treatment of People With Ebola Virus DiseasePivotal-lookingCompleted
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT03719586 · 681 participants · Start Nov 21, 2018 · Primary completion Sep 9, 2019
Drug: ZMapp; Remdesivir and 2 more · For: Ebola Virus
Sites: Bethesda, Maryland; Kinshasa Gombe, Democratic Republic of the Congo
- Prophylaxis Vaccine Antibodies EbolaStatus unknown
ANRS, Emerging Infectious DiseasesGovernment (non-federal)
NCT04822376 · 250 participants (planned) · Start Oct 17, 2021 · Primary completion Apr 2022
Drug: ansuvimab; Ervebo · For: Ebola Virus Disease
Sites: N'Zerekore, Guinea
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT03478891 · 19 participants · Start May 16, 2018 · Primary completion Mar 20, 2019
Drug: VRC-EBOMAB092-00-AB (MAb114) · For: Healthy Adult Immune Responses to Vaccine
Sites: Bethesda, Maryland
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective for unapproved indication1
- ebola disease1
- foetal exposure during pregnancy1
- low birth weight baby1
- maternal exposure during pregnancy1
- off label use1
- postpartum haemorrhage1
- premature baby1
- premature delivery1
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2024 | 2 |
| 2025 | 1 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- A systematic review of Ebola virus disease outbreaks and an analysis of the efficacy and safety of newer drugs approved for the treatment of Ebola virus disease by the US Food and Drug Administration from 2016 to 2020.
Sivanandy P, Jun PH, Man LW, et al. · J Infect Public Health 2022 · Systematic Review
Sponsor: Ridgeback Biotherapeutics
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.